Baccelli Andrea, Rinaldo Rocco F, Haji Gulammehdi, Davies Rachel J, Lo Giudice Francesco, Gin-Sing Wendy, Vigo Beatrice, Centanni Stefano, Gibbs J Simon R, Howard Luke S
Department of Respiratory Medicine, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Respiratory Diseases Unit, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, Department of Medical Sciences, University of Turin, Turin, Italy.
Eur Respir J. 2025 Aug 22;66(2). doi: 10.1183/13993003.02026-2024. Print 2025 Aug.
Current guidelines recommend a four-strata model based on World Health Organization Functional Class (WHO FC), 6-min walk distance (6MWD) and serum levels of brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) for risk stratification in patients with pulmonary arterial hypertension (PAH) during follow-up. We explored the relevance of using cardiopulmonary exercise testing (CPET) as the exercise parameter in place of 6MWD at first reassessment after treatment initiation in PAH.
Incident treatment-naive patients with idiopathic, heritable, drug/toxin-induced and connective tissue disease-associated PAH between 2010 and 2022 were analysed. Correlations between CPET and haemodynamic and right ventricular function parameters were explored, and those which were significant were carried forward to assess association with survival. Independent predictors were used to derive a four-strata CPET score.
262 patients were included. CPET parameters showed better correlations with haemodynamics and right ventricular function than 6MWD. The CPET score included peak oxygen uptake (peak ), the slope relating minute ventilation to carbon dioxide production ( / slope) and peak oxygen pulse. The four-strata model based on WHO FC, BNP and CPET score predicted survival at the time of the first re-evaluation, with better accuracy than the model including 6MWD (C-index 0.81 0.71). The CPET score on its own also performed well (C-index 0.82) with a greater spread between categories. Treatment-associated changes in peak predicted survival, while changes in 6MWD did not.
A simplified four-strata CPET score either alone or included with BNP and WHO FC accurately predicts survival at follow-up in PAH.
当前指南推荐基于世界卫生组织功能分级(WHO FC)、6分钟步行距离(6MWD)以及脑钠肽(BNP)或N末端脑钠肽原(NT-proBNP)血清水平的四分层模型,用于肺动脉高压(PAH)患者随访期间的风险分层。我们探讨了在PAH治疗开始后的首次重新评估中,使用心肺运动试验(CPET)作为运动参数替代6MWD的相关性。
分析了2010年至2022年间初治的特发性、遗传性、药物/毒素诱导性和结缔组织病相关性PAH患者。探讨了CPET与血流动力学及右心室功能参数之间的相关性,并将具有显著相关性的参数用于评估与生存的关联。使用独立预测因子得出四分层CPET评分。
纳入262例患者。与6MWD相比,CPET参数与血流动力学及右心室功能的相关性更好。CPET评分包括峰值摄氧量(peak )、分钟通气量与二氧化碳产生量的斜率( / 斜率)以及峰值氧脉搏。基于WHO FC、BNP和CPET评分的四分层模型在首次重新评估时预测生存情况,其准确性高于包含6MWD的模型(C指数0.81对0.71)。单独的CPET评分表现也良好(C指数0.82),各分层之间的差异更大。峰值 的治疗相关变化可预测生存,而6MWD的变化则不能。
单独的简化四分层CPET评分或与BNP和WHO FC一起使用,均可准确预测PAH患者随访期间的生存情况。